Von Hippel-Lindau (VHL) disease is associated with a range of tumor types that require timely recognition and coordinated management. Accurate diagnosis depends on careful evaluation of clinical presentation, imaging findings, and genetic assessment, as these insights…
Von Hippel-Lindau (VHL) disease is a rare, heritable condition in which approximately 80% of affected individuals have an affected parent, underscoring the critical importance of early identification and surveillance. However, its rarity and variable presentation can…
Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of ongoing treatment continues to impact patient quality…
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…
Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early…
Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early…
Neurofibromatosis Type 1 (NF1) requires a nuanced clinical approach due to its diverse neuro-oncologic manifestations and potential for significant morbidity. To facilitate timely diagnosis and intervention, health care professionals must recognize early neurologic signs and tumor…
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…
Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL). Patients and caregivers rely on their care team…